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Beginning of Battle against NPC
in Hong Kong
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NPC  : Invariably Lethal in pre-RT Era
“Thoroughness was not attainable 
t th b tt f d ita  e o om o  a eep p
Surgery merely added to   
anemia of cancerous cachexia”
Jackson 1901
Obj tiec ves




Ad  i  th  B ttlvances n e a e
against NPC
U i  E id i ln que p em o ogy
Skewed geographic & ethnic distribution
Globocan 2002, IARC 






in Southern Chinese Diet
Ch  i  Lif  St l  i  H  Kanges n e y e n ong ong
1950s → 21st Century
NPC  Ch i  E id i l: ang ng p em o ogy
Data from Hong Kong Cancer Registry 1980-2004





A Lee in Harari et al (Eds), In press
Function Preservation and Quality of Life in Head and Neck Radiotherapy
Ad  i  th  B ttlvances n e a e
against NPC





CT > X ray
Upstage to T3-4






More accurate tumor delineation
Current Recommendation on Work Up-
Improved Staging Accuracy by PET
Stage Distribution (%) in 95 patients
Work-up by MRI (head & neck), CXR, bone scan, abdominal U/S, FDG-PET
With PET
With t PET I II III IVA IVB IVCou  
I 3
II 12





Staging Systems for NPC
Past AJCC / UICC Systems
AJCC 1976, 83
    
UICC 1974, 82
AJCC / UICC 1987
One set of principle
for all Head & Neck Cancers
Different Staging Systems
W t E t




   
Perez 1969
Ch & Fl t h
 
Ho 1978
Hen  e c er 1971
Moench & Philips 1972
uang 1980
Li et al. 1983
De The & Ito 1978
Neel & Taylor 1989
Teo et al. 1991
Min et al. 1994   
Current AJCC/UICC System (5 6th Ed)-
Customized System for NPC
Introduced in 1997
based on 
Extensive review of specific data
Combining strengths of 
Ho’s System & AJCC/UICC 4th Ed


































A Lee, IJC 1999
Year
0 2 4 6 8 10
Year
0 2 4 6 8 10
Advances in TNM Staging










A Lee, IJC 1999
0
I II III IV
Data Supporting AJCC/UICC 5-6th Ed
Author Period StagingOrigin







































Proposed modifications of current AJCC/UICC  System 
T2a → T1
N3a → N2
T2N0 → Stage I
Author Period StagingOrigin
Lee (n = 2687)
Low (n = 677)









China    
Disease-Specific Survival












AJCC/UICC 5-6th Ed Proposed
A Lee, CO 2004
Primary Tumor Volume















































P ti  Si ifi  f GTV Prognos c gn cance o _
Local Control Failure-Free Survival
GTV_P < 15 cc
GTV_P > 15 cc










GTV_P > 15 cc
P
r
97% vs 82% (3-yr)
P = 0 002
85% vs 65% (3-yr)
P = 0 003
Year
 .




         
Ways to Improve Prognostic Accuracy
Use of Primary Tumor Volume as T‐category criteria
Overall Survival in 129 CT-staged patients (1994-96)
Year
Multivariate analyses
GTV_P Significant: HR increase to 7, 18 & 26 (p < 0.003)
T-category Non-significant (p >0 58)  .
Chen, Cancer 2004
Ways to Improve Prognostic Accuracy
Pre-Treatment EBV-DNA (esp. non-keratinizing NPC)
T IJROBP 200L JCO 2006Li NEJM 2004 wu,  7eung,  n,  
Le, Human Cancer Biol 2005
Prognostic value of EBV‐DNA     
376 patients with non-keratinizing NPC of all stages
Leung, JCO 2006
Prognostic value of EBV-DNA
90 pt Stage I-II NPC with median FU 45m






IIB – EBV-DNA <4000 copies/mL 0
IIB – EBV-DNA ≥4000 copies/mL 37%
Leung, Cancer 2003
Refinement on Work-up & Treatment of NPC
History + physical examination
Endocopy +/ biopsy
MRI (± CT bone window)
 -






Low risk High 
risk
RT alone Chemo-RT
Ad  i  th  B ttlvances n e a e
against NPC
Ad t f M lt  RTven o egavo age
First Breakthrough 
“25% of patients alive at 5-year!”     
Moss 1965
Result by 2D-RT Alone in 1950-60s
Enigma of Nasopharyngeal Cancer
by L. Peters, Aust Radiol 1971









Ho (Hong Kong 1969)
Peters (Australia 1971)  
2D RT Technique
HoPerez
Principles and Practice of Radiation Oncology, 5th Edition
A. Lee, In: Halperin, Perez, Brady (Ed)
5  S i l b  2D RT Al-year urv va y - one
Author Period Survival

















DSS   52
OS 59      
5  S i l b  2D RT i  1990-year urv va y - n s
Author Period Chemo DSS OS





















Palazzi (Italy) 1990-1999 60% 74 72
*10% 3D-RT
Total Dose for Local Control
>67 Gy: significant improvement
Marks 1982; Vikram 1985
T1-2 tumors: 
≥70 Gy better than 60 Gy (94% vs 76%)     
>70 Gy better than 66-70 Gy (100% vs 80%)
Mesic 1981
     
Perez 1992
T3-4 tumors: no difference even if >70 Gy
Dose Response Relationship
2426 pt. treated by 2D-RT to 66 Gy (1996-2000)
(511 pt. given chemotherapy)
T1-2a T3-4
Independent value of Boosting on multivariate analyses
Significantly improve local control in RT alone subgroup
Non-significant in chemo-RT subgroup (p = 0.16)
Teo, R&O 2006
      
Dose Escalation
Conventional fractionation + boost Brachytherapy
Brachytherapy Boost
Retrospective comparison on local control (5-yr)
Author Local controlTumor PDose (Gy)
Chang 94-80% Vs 74%T1 0.0165-68
+ 5-16.5




Wang 91% Vs 60%T1-2 <0.0160-64
+ 7-10
Conventional RT + boost 
by stereotactic RT/ Radiosurgery
Stereotactic Boost
Hara (2008) Chen (2006)
No. of pt. (median FU) 82 (3.4 yr) 64 (2.6 yr)
Dose (Gy): ERT 66 65-68
+ SRT
Chemotherapy
7-15 / 1 Fr
85%
12-15 / 3 Fr
81%
Local fail re free 98% (5 ) 93% (3 ) u -  -y  -y
Overall survival 69% (5-y) 85% (3-y)
Temporal lobe necrosis 12%
Retinopathy 4%
Fatal epistaxis 5%
Dose Escalation by RT alone for T3-4
5-yr rate (%) 81 Gy*
32 pt (96 97)
70.2 Gy
32 pt (92 95)
P
value  -   -
Tumor control
Local failure free 61 61 0 65 - .
Overall survival 43 41 0.98
Late Toxicities
Xerostomia 98 86 0.01
Deafness 70 50 0.02
Temporal lobe necrosis 18 9 0.04
*2D 61.2 Gy + 3D conformal RT 19.8 Gy Yeh, AJCO 2007
Randomized Trials on Accelerated Fractionation











0 1 2 3 4 5 6
0 .0
159 pt (1993-1995) 154 pt (1997-2003) 189 pt (1999-2004)  
29% T3-4
2.5 Gy QD x 8 
2.5 Gy QD x 16
1 6 BD 32
  
45% T3-4
2 Gy QD x 35
1 6 BD 44
  
100% T3-4
CF: 2 Gy QD, 5 Fr/wk
AF: 2 Gy QD, 6 Fr/wk
.  Gy  x .  Gy  x 
± concurrent-adjuvant chemo
Randomized Trials on Accelerated Fractionation




,  ,   ,  
xerostomia Skin fibrosis







0 1 2 3 4 5 6
.0




2.5 Gy QD x 8 
2.5 Gy QD x 16
1 6 BD 32
  
45% T3-4
2 Gy QD x 35
1 6 BD 44
  
100% T3-4
CF: 2 Gy QD, 5 Fr/wk
AF: 2 Gy QD, 6 Fr/wk
.  Gy  x .  Gy  x ± concurrent-adjuvant chemo
Brain Necrosis by 1 6 Gy BID / TID.
Author Dose schedule TL necrosis
Wang
 





67.2 Gy (1.6 BID)




.   .  - .  
72 Gy (1.6 TID) ↑
Jen
Dauod
70 Gy (1.6 BID)
70.4 Gy (1.6 BID)
27%
Nil
Risks of Different AF Schedules
Same 2D technique in single institute     
(inter-fraction interval - 6 hr)







J IJROBP 2001en,  
Distant Failure (5-yr) after RT Alone






































A Lee (HKNPCSG), IJROBP 2005
Randomized Trials on Chemo-RT Vs RT 
(up to 2004)






































95 01wong  –












































Kwong Concurrent + Adjuvant
Meta-Analysis on 1753 patient from 8 Trials
Absolute Benefit by Chemo-RT
i S i l O ll S i l
     
D sease-Free urv va
52% Vs 42% (5-yr)
vera  urv va















0 2 4 6 8 10
0.0
0.2
0 2 4 6 8 10
Time (Years) Time (Years)
Baujat et al, IJROBP 2006
Meta-Analysis on 1753 patient from 8 Trials


















Baujat et al, IJROBP 2006
Trials using Concurrent cisplatin 
+ Adjuvant cisplatin-fluorouracil































































JCO 1998 JCO 2005 JCO 2005 IJROBP 2008
Trials using Concurrent cisplatin 
+ Adjuvant cisplatin-fluorouracil

























































JCO 1998 JCO 2005 JCO 2005 IJROBP 2008
6543210 6543210
.







Receive Planning Request Arrange Planning Appointment Oncologist Consultation Explain Planning Procedures to 
Patient
? Require MouldMould Making (MoLT)Main Procedures for Teletherapy
Y
N
Simulation ? Require Simulation








NBeam Data Acquisition, machine 
calibration by Medical Physicist
  
Prepare Treatment Record & Calculate DoseAccessories making, if any (MoLT)
Check Accessories Senior Radiographer Check Plan Verification if required 
Start Treatment in 
Treatment Machine
Supporting ServicesKey: Work Flow
Meticulous Immobilization
Head & Shoulder Cast
Headrest on Alpha Cradle shoulder support
Head Extension (base-board)
A Lee
Accurate Delineation of GTV
Image Fusion 
Diagnostic MRI ↔ Planning CT
A Lee
GTV: Fusion of MRI & PET-CT 
MRI PET-CTPlanning CT 
A Lee
Intensity-Modulated RT Technique




IMRT: Improve Dose Distribution
2D IMRT
A Lee




IMRT: Prescription at PTV1
Author Gy/ Fr Total Gy Special RT
Bucci (US)* 2.12 70 22% boost
Wolden (US) 2.34 70.2 80% AF
Le (US) 2.2 66 All SRT boost
Kam (HK) 2 66 56% boost
Kwong1 (T1) (HK) 2-2.06 68-70 -
Kwong2 (T3-4) (HK) 2.17 76 -
Chong (China) 2.33–2.56 64-70
SW Lee (Korea) 2.4 72
A Lee (HK) 2 70
Defining Target Volume
RTOG 0615 PYNEH
CTV1 (GTV-P & GTV-N) + 5 mm GTV-P + 5 mm, GTV-N + 5-10 mm
Whole NP
CTV Whole NP2  
(GTV-P & GTV-N) + 10 mm GTV-P + 10 mm, GTV-N + 10-15 mm
parapharyngeal space, pterygoid fossa, posterior nasal 
f & ill i k ll b i f i h id iossa  max ary s nus, s u  ase, n er or sp eno  s nus, 
anterior clivus,  cavernous sinus (if T3-4)
Bilateral retropharyngeal ± IB LN
Level II-V LN Level II-III,Va LN (if N0)
CTV3 Uninvolved lower neck
PTV CTV + 5 mm CTV + 3 mm




(2 12 G 33 F )
GTV
PTV_70 Gy
(2 G 35 F )
PTV_59.4 Gy
(1.8 Gy x 33 /Fr)
PTV_61.25 Gy
(1.75 Gy x 35 /Fr)
.  y x  r  y x  r
    
PTV_54 Gy
(1.64 Gy x 33Fr)
    
PTV_52.5 Gy
(1.75 Gy x 30Fr)
Prioritization of Organs at Risk
RTOG 0615 PYNEH
Brainstem / Spinal cord








Lens / EyesLens / Eyes     
Cochlea
Glottic Larynx / Esophagus
Oral cavity (uninvolved)
Planning Dose Constraint
Priority 1: Critical Organs at Risk
OAR 
(PRV)
RTOG 0615 PYNEH 
Ideal Acceptable
Spinal cord ≤1% V >50 Gy ≤45 Gy ≤1 cc >50 Gy
Brainstem ≤1% V >60 Gy ≤54 Gy ≤1% V >60 Gy
Optic chiasma
≤54 Gy
≤54 Gy ≤60 Gy
Optic nerves ≤54 Gy ≤60 Gy
Temporal lobes <65 Gy & <70 Gy & 
≤1% V >60 Gy ≤1% V >65 Gy
Brachial plexus ≤66 Gy ≤66 Gy ≤1 cc >66 Gy
Mandible/ TMJ ≤70 Gy or
≤1 cc >75 Gy
(Priority 3)
Planning Dose Constraint
Priority 2: Tumor Targets
RTOG 0615 PYNEH
Ideal Acceptable
GTV 100% V ≥98% D 99% V ≥95% D
PTV 95% V ≥100% D 
99% V ≥93% D
100% V ≥95% D 95% V ≥100% D 
99% V ≥93% D
(PTV 70) 20% V 77 G 10% V 75 G 20% V 77 G_ <   ≥  y
<5% V ≥80 Gy
Mean D ≤ 74 Gy
<   ≥  y <   ≥  y
Planning Dose Constraint
Priority 3: Organs at Risk (Intermediate Importance)
OAR RTOG 0615 PYNEH 
     
Ideal Acceptable
Mandible/ TMJ (Priority 1) ≤1 cc >70 Gy ≤1 cc >75 Gy
Parotid gland Mean D <26 Gy Mean D <26 Gy ≥50% V <30 Gy    
≥50% V <30 Gy
      
Pituitary ≤60 Gy ≤65 Gy
Lens (Priority 4) ≤6 Gy ≤10 Gy
Eyeball (Priority 4) ≤50 Gy Mean D <35 Gy
Pl i  D  C t i tann ng ose ons ra n
Priority 4: Organs at Risk (Low importance)
OAR RTOG 0615 PYNEH
Ideal Acceptable
Eyes ≤50 Gy (Priority 3)
Lens ≤25 Gy (Priority 3)
Cochlea ≤5% V ≥55 Gy Mean D <50 Gy <55 Gy
Larynx Mean D <45 Gy Mean D <45 Gy
Esophagus/ Mean D <45 Gy Mean D <45 Gy 
pharynx
     
Oral cavity Mean D <40 Gy Mean D <40 Gy Mean D <50 Gy
IMRT at PYNEH




+ soft tissue  
Set-up Deviations
Study of 1120 images by OBI in 32 patients
% of images with deviation
>2mm >3mm >4mm >5mm
AP direction 3.2 1.1 0.2 0.1
Lateral direction 1.1 0.2 0 0
Longitudinal direction 4.0 1.3 0.3 0
D e v i a t i o n s  o v e r  3 m m  ( 2 5  c a s e s )
0 . 6
- 0 . 6
- 0 . 4





















A. LeeA P L a t L o n g
Adaptive RT: Re-Plan at Interval
Dose to spinal cord
20Gy0Gy
0Gy A Lee20Gy
IMRT: Treatment in Different Centers
Author Gy/ Fr Total Gy Special RT Chemotherapy
Bucci 2.12 70 22% boost 90%
Wolden 2.34 70.2 80% AF 93%
Kam 2 66 56% boost 30%
Kwong1 2 2 06 68 70 0- . - -
Kwong2 2.17 76 - 68%
Chong 2.33–2.56 64-70 - 23%
SW Lee 2.4 72 - 90%
IMRT: Tumor Control
Author Rate Local Nodal Distant Survival
Bucci 4-y 96% 98% 72% 74%
Wolden 3-y 91% 93% 78% 83%
Kam 3-y 92% 98% 79% 90%
Kwong1 2 y 100% 94% 94% NR-
Kwong2 2-y 96% - 94% 92%
Chong 3-y 99% 99% 88% 86%
SW Lee 2-y 88% 88% 90% NR
Quality of Life for NPC Survivors
Survivor following 2D-RT vs normal population    
Significantly worse in most functional domains
Fang, IJROBP 2002
3D conformal/IMRT vs 2D±3D boost
Significantly better global QOL (63 vs 51, p < 0.01)
OR for QOL: 2.01, OR for xerostomia: 0.37 (p < 0.01)
Fang, Cancer 2007
Longitudinal comparison of IMRT vs 3D conformal
No significant difference in most scales up to 24 m
Fang, IJROBP 2008
IMRT: Parotid Sparing
Randomized trials on IMRT vs 2D-RT
Kam, JCO 2007
60 pt (T1-2N0-1M0)51 pt (T2N0-1M0)
Pow, IJROBP 2004
Significantly better recovery of salivary flow




By MRI & PET/CT
Cannon & N Lee, IJROBP 2008










































Torrential Epistaxis 1%* - 4%#
Bleeding site:
*Unknown (N. Lee, IJROBP 02)
#Carotid pseudo-aneurysm (Kwong IJROBP 06),  
Pseudo-aneurysm at Internal Carotid A  .
Emergency treatment 
stent / embolization
Kind permission by 
KY Pang
Chemo-RT: Increase in Late Toxicity
1 0







28% vs 13% (3-yr)
P 0 026
AF+C: 34%, CF+C: 31%























A Lee (HKNPCSG) JCO 05, IJROBP 06
0 1 2 3 4 5 66543210
Late Toxicity after Conformal RT
422 pts treated at PYNEH (1998–2003)
3D conformal RT: 2 Gy daily to 70 Gy        
median follow-up 4.4 years
RT + concurrent chemotherapy
Chemo-RT vs RT 
37% vs 27% (5-yr)
RT + boost (5 Gy in 2 Fr)
   
P = 0.009
RT alone
A Lee, IJROBP 2008
Multivariate analyses on Late Toxicity
Deafness All Toxicity 
A 1 05 (1 03-1 07) 1 04 (1 02-1 05)ge (per year) .  . .p < 0.001
.  . .
p < 0.001
T-category (T3-4 vs T1-2) NS NS
Boost (Yes vs no) NS NS
Fractionation (AF vs CF) NS NS




A Lee, IJROBP 2008
Temporal Lobe Necrosis 







 y a one
+ concurrent chemotherapy 0.177
4.8%+ boost (5 Gy in 2 Fr) 0.015
0Brachytherapy (n = 22)
8.3%SRT (n = 33)
(additional dose to TL by SRT: 0 08 (± 0 06) Gy)
A Lee, IJROBP 2008
      .  .   
Narrow Therapeutic Margin
Adequate Coverage & Maximum Protection   
Local recurrence Brain necrosis  





• Speed: 2-8 times faster
U if• n orm target coverage
• Improved normal tissue sparing
• Reduced peripheral dose  
Concurrent-Adjuvant CRT 
+ Altered Fractionation









70 Gy/ 6 wk
72 Gy/ 6 wk
50
63
Jian 91%P(+F)-PF>77% 74 Gy/ 7 wk48
Concurrent-adjuvant Chemo-RT with 
NPC 9902 Trial: 189 pt with T3 4N0 1M0 NPC
Accelerated Fractionation














74% vs 70% (3-yr)
P = 0.80.0
0.2
0 1 2 3 4 5 6
A Lee (HKNPCSG), IJROBP 2006
Tumor Regression by Induction Chemo




(p < 0 001) .
volume <70 Gy
10.2% vs 3.8% 
(p = 0.017)
A Lee, R&O 2008
Induction-Concurrent Chemo-RT





































Lee 71% (3)PF-P100%49 AF
Yau 76% (3)PG-P100%37 AF  
T = docetaxel, T = paclitaxel, G = gemcitabine
Randomized phase II study
64 pt Induction P-docetaxel + concurrent P
Stage III-IVB concurrent P
Overall SurvivalProgression-Free
80% v 71% (2-y), p = 0.11 93% v 76% (2-y), p = 0.01
Hui, Proc ASCO 2007
Neutropenia 100% vs 16%, p <0.001
HKNPCSG 0501 Trial-
A Randomized Phase III Trial on Stage III-IVB NPC
(T t 798 t)
ARM 1 ARM 2 ARM 3



















(X, Capecitabine)Study PI: A Lee, R Ngan
Value of Post Treatment EBV DNA- -
Twu, IJROBP 2007Le, Human Cancer Biol 2005
Chan, JNCI 2002 Lin, IJROBP 2007
HKNPCSG - 0502 Trial
Risk stratification by Plasma EBV DNA







     
150 pt with detectable
R
A
N Arm A 
Cisplatin/Carboplatin
(6mon)(0 mon)
    
plasma EBV-DNA 




















Study PI: A. Chan, R. Ngan
Epidermal Growth Factor Receptor
54 pt. with Stage III-IV NPC 
89% demonstrated EGFR expression   
72% staining extent >25%






48% v 86% (5-y)
  
60% v 93% (5-y)
Chua, IJROBP 2004 
Anti EGFR Therapy for NPC-
Cetuximab-carboplatin
60 pt. with metastatic/recurrent NPC 
(progressed < 1 yr after cisplatin-based Rx)
12% partial response
Time to progression (median): 3 mon
Chan, JCO 2005
Phase II study of concurrent cetuximab-cisplatin & RT 
for Stages III-IV NPC
Study PI: B. Ma
Vascular Endothelial Growth Factor   
VEGF(%) positive in 103 pt. with NPC 
Recurrence vs No recurrence = 77% vs 61% , p = 0.015     




VEGF -ve 50 m 47 m
VEGF +ve 39 m 35 m
Krishna, Virus Research 2005 
   
RTOG 0615-
Phase II Study on Stage IIB-IVB (Target: 46 pt)
Concurrent-Adjuvant chemo-RT + Bevacizumab
Concurrent Phase Adjuvant Phase
Bevacizumab: 15 mg/kg 
Days 1, 22, 43
    
Bevacizumab: 15 mg/kg 
Days 64, 85, 106
Cisplatin: 100 mg/m2
Days 1 22 and 43
      
Cisplatin: 80 mg/m2
Days 64, 85, 106
3D-CRT or IMRT
 , ,  
5-Fluorouracil: 1 g/m2
Days 64-67, 85-88, 106-109 
Gross disease PTV: 70 Gy/33 Fr
Study PI: N. Lee et al
Novel Therapies




 DNA hypermethylation or 
Histone acetylation
Immunotherapy for NPC
• Adoptive Rx for refractory NPC:
A tologo s EBV targeted c toto ic T l mphoc teu u  -  y x  - y y










Active immunization with EBV vaccine
-   
•     






Decreasing incidence & Improving survival
80
80%

















Within our Lifetime 
